Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Feb;7(3):61.
doi: 10.21037/atm.2018.12.68.

Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer

Chong-Kin Liam  1
Affiliations
Editorial

Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer

Chong-Kin Liam. Ann Transl Med. 2019 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: CK Liam: advisory board and speaker’s fees and research grant from Astra-Zeneca; advisory board and speaker’s fees and research grant from Boehringer Ingelheim.

Comment on

References

    1. Cortot AB, Jänne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev 2014;23:356-66. 10.1183/09059180.00004614 - DOI - PMC - PubMed
    1. Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012;77:556-60. 10.1016/j.lungcan.2012.05.092 - DOI - PubMed
    1. Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non-small-cell lung cancer. Cancer 2010;116:1336-43. 10.1002/cncr.24877 - DOI - PubMed
    1. Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016;22:5130-40. 10.1158/1078-0432.CCR-16-0399 - DOI - PubMed
    1. Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012;70:399-405. 10.1007/s00280-012-1929-4 - DOI - PubMed